Early-stage life sciences venture firm MPM Capital has expanded its San Francisco based investment team with the appointment of Ed Hurwitz, JD, MBA, as Managing Director.
With more than 25 years of biotech and life science investment, finance and operations experience, Hurwitz brings to this role a track record of overseeing innovative investment funds, sourcing investment opportunities and working with portfolio companies to develop innovative products and exceed financial goals.
Hurwitz was most recently Founder and Managing Director of Precision BioVentures LLC where he focused on developing novel investment strategies and building a portfolio of businesses. While there, he co-founded Viewpoint Therapeutics, an innovative ophthalmology company.
Prior to this, he was a Director of two funds at Alta Partners — Alta BioPharma Management III and Alta Partners Management VIII.
Hurwitz currently serves on the Boards of Directors for Applied Genetic Technologies Corporation, Macrogenics, Inc. and Viewpoint Therapeutics. While at Alta, he also led investments and served on the Boards of Directors of Avid Radiopharmaceuticals (acquired by Lilly), Calistoga Pharmaceuticals (acquired by Gilead), Cara Therapeutics, FoldRx Pharmaceuticals (acquired by Pfizer), and Taligen Therapeutics (acquired by Alexion).
Over the course of his career, Hurwitz has been a Senior Vice President and CFO of Affymetrix, a pioneer microarray supplier, and a biotechnology research analyst for both Robertson Stephens & Company and Smith Barney Shearson.
Led by Ansbert Gadicke and Luke Evnin, MPM Capital is an early-stage life sciences venture firm founding and investing in companies that seek to cure major diseases by translating scientific innovations into positive clinical outcomes.